U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H9NO2
Molecular Weight 139.1519
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEFERIPRONE

SMILES

CN1C=CC(=O)C(O)=C1C

InChI

InChIKey=TZXKOCQBRNJULO-UHFFFAOYSA-N
InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3

HIDE SMILES / InChI

Molecular Formula C7H9NO2
Molecular Weight 139.1519
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://pubchem.ncbi.nlm.nih.gov/compound/deferiprone#section=Top; http://www.ncbi.nlm.nih.gov/pubmed/12825969

Deferiprone (trade name Ferriprox) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is an orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body. All the adverse effects of deferiprone are considered reversible, controllable and manageable. These include agranulocytosis with frequency of about 0.6%, neutropenia 6%, musculoskeletal and joint pains 15%, gastrointestinal complains 6% and zinc deficiency 1%.

Originator

Curator's Comment: ApoPharma began formal development of deferiprone in 1993 (http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-adcom/documents/document/ucm275607.pdf; http://tircon.eu/tircon-partners/apopharma)

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
FERRIPROX

Approved Use

Indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival

Launch Date

2011
Primary
FERRIPROX

Approved Use

Indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival. Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias.

Launch Date

2011
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
64.8 μM
25 mg/kg single, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
118.8 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
150.8 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
60.8 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
35.2 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
51.4 ug/mL
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
54.4 ug/mL
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
34.1 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
30.6 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
33.4 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
43.3 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
15001 μM × min
25 mg/kg single, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
205.5 ug*h/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
331.2 ug*h/mL
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
152.1 ug*h/mL
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
95.4 ug*h/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
168 min
25 mg/kg single, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.58 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
2.58 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
3.34999999999999 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
2.5 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
2.6 h
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1.8 h
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1.8 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1.77 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
2.03 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
2.2 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
30 mg/kg 2 times / day multiple, oral
Recommended
Dose: 30 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg/kg, 2 times / day
Sources: Page: p.3
unhealthy, 29–71
n = 10
Health Status: unhealthy
Condition: Infratentorial superficial siderosis
Age Group: 29–71
Sex: M+F
Population Size: 10
Sources: Page: p.3
Disc. AE: Neutropenic sepsis, Fatigue...
AEs leading to
discontinuation/dose reduction:
Neutropenic sepsis (30%)
Fatigue (10%)
Sources: Page: p.3
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Disc. AE: Arthralgia, Joint effusion...
AEs leading to
discontinuation/dose reduction:
Arthralgia (non-serious)
Joint effusion (non-serious)
Nausea (non-serious)
Abdominal discomfort (non-serious)
Fatigue (non-serious)
Joint swelling (non-serious)
Epistaxis (non-serious)
Upper respiratory tract infections (non-serious)
Upper abdominal pain (non-serious)
Vomiting (non-serious)
Palpitation (non-serious)
Sources: Page: e475
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.3
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.3
Disc. AE: Aspartate aminotransferase increased, Alanine aminotransferase increased...
AEs leading to
discontinuation/dose reduction:
Aspartate aminotransferase increased (0.78%)
Alanine aminotransferase increased (0.16%)
Sources: Page: p.3
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.4
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.4
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (1.6%)
Vomiting (1.6%)
Abdominal pain (1.6%)
Sources: Page: p.4
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Sources: Page: p.1
Disc. AE: Agranulocytosis, Fetal damage...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis (grade 3-5)
Fetal damage
Sources: Page: p.1
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Other AEs: Neutropenia, Intestinal dilatation...
Other AEs:
Neutropenia (serious, 5 patients)
Intestinal dilatation (serious, 1 patient)
Intestinal obstruction (serious, 1 patient)
Volvulus (serious, 1 patient)
Obstruction (serious, 1 patient)
Pyrexia (serious, 1 patient)
Bacterial disease carrier (serious, 1 patient)
Bronchitis (serious, 2 patients)
Device related infection (serious, 1 patient)
Pneumonia (serious, 2 patients)
Wound infection (serious, 1 patient)
Chemical eye injury (serious, 1 patient)
Postoperative ileus (serious, 1 patient)
Toxicity to various agents (serious, 1 patient)
Unintentional medical device removal (serious, 1 patient)
Oromandibular dystonia (serious, 1 patient)
Device malfunction (serious, 1 patient)
Urinary bladder rupture (serious, 1 patient)
Choking (serious, 1 patient)
Cough (serious, 1 patient)
Respiratory disorder (serious, 1 patient)
Colectomy (serious, 1 patient)
Intestinal anastomosis (serious, 1 patient)
Intrathecal pump insertion (serious, 1 patient)
Laparotomy (serious, 1 patient)
Medical device battery replacement (serious, 2 patients)
Tracheostomy (serious, 1 patient)
Tracheostomy tube removal (serious, 1 patient)
Wound treatment (serious, 1 patient)
Thrombosis (serious, 1 patient)
Anaemia (below serious, 12 patients)
Influenza (below serious, 3 patients)
Pain (below serious, 4 patients)
Bronchitis (below serious, 7 patients)
Nasopharyngitis (below serious, 11 patient)
Rhinitis (below serious, 4 patients)
Upper respiratory tract infection (below serious, 8 patients)
Viral infection (below serious, 4 patients)
Laceration (below serious, 6 patients)
Body temperature increased (below serious, 3 patients)
Neutrophil count decreased (below serious, 10 patients)
Serum ferritin decreased (below serious, 19 patients)
Iron deficiency (below serious, 9 patients)
Arthralgia (below serious, 8 patients)
Muscle spasms (below serious, 3 patients)
Pain in extremity (below serious, 10 patients)
Dystonia (below serious, 25 patients)
Migraine (below serious, 3 patients)
Urinary incontinence (below serious, 3 patients)
Cough (below serious, 10 patients)
Oropharyngeal pain (below serious, 9 patients)
Rhinorrhoea (below serious, 4 patients)
Hyperhidrosis (below serious, 3 patients)
Rash (below serious, 4 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fatigue 10%
Disc. AE
30 mg/kg 2 times / day multiple, oral
Recommended
Dose: 30 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg/kg, 2 times / day
Sources: Page: p.3
unhealthy, 29–71
n = 10
Health Status: unhealthy
Condition: Infratentorial superficial siderosis
Age Group: 29–71
Sex: M+F
Population Size: 10
Sources: Page: p.3
Neutropenic sepsis 30%
Disc. AE
30 mg/kg 2 times / day multiple, oral
Recommended
Dose: 30 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg/kg, 2 times / day
Sources: Page: p.3
unhealthy, 29–71
n = 10
Health Status: unhealthy
Condition: Infratentorial superficial siderosis
Age Group: 29–71
Sex: M+F
Population Size: 10
Sources: Page: p.3
Abdominal discomfort non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Arthralgia non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Epistaxis non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Fatigue non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Joint effusion non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Joint swelling non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Nausea non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Palpitation non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Upper abdominal pain non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Upper respiratory tract infections non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Vomiting non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Alanine aminotransferase increased 0.16%
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.3
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.3
Aspartate aminotransferase increased 0.78%
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.3
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.3
Abdominal pain 1.6%
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.4
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.4
Nausea 1.6%
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.4
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.4
Vomiting 1.6%
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.4
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.4
Fetal damage Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Sources: Page: p.1
Agranulocytosis grade 3-5
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Sources: Page: p.1
Cough below serious, 10 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Neutrophil count decreased below serious, 10 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Pain in extremity below serious, 10 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Nasopharyngitis below serious, 11 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Anaemia below serious, 12 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Serum ferritin decreased below serious, 19 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Dystonia below serious, 25 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Body temperature increased below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Hyperhidrosis below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Influenza below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Migraine below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Muscle spasms below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Urinary incontinence below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Pain below serious, 4 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Rash below serious, 4 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Rhinitis below serious, 4 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Rhinorrhoea below serious, 4 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Viral infection below serious, 4 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Laceration below serious, 6 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Bronchitis below serious, 7 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Arthralgia below serious, 8 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Upper respiratory tract infection below serious, 8 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Iron deficiency below serious, 9 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Oropharyngeal pain below serious, 9 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Bacterial disease carrier serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Chemical eye injury serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Choking serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Colectomy serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Cough serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Device malfunction serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Device related infection serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Intestinal anastomosis serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Intestinal dilatation serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Intestinal obstruction serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Intrathecal pump insertion serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Laparotomy serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Obstruction serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Oromandibular dystonia serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Postoperative ileus serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Pyrexia serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Respiratory disorder serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Thrombosis serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Toxicity to various agents serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Tracheostomy tube removal serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Tracheostomy serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Unintentional medical device removal serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Urinary bladder rupture serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Volvulus serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Wound infection serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Wound treatment serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Bronchitis serious, 2 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Medical device battery replacement serious, 2 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Pneumonia serious, 2 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Neutropenia serious, 5 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Overview

Overview

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
minor
no
no
no
no
no
no
no
no
yes
yes
yes
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Molecular factors affecting the complex formation between deferiprone (L1) and Cu(II). Possible implications on efficacy and toxicity.
2001
Genotoxicity of iron chelators in L5178Y mouse lymphoma cells.
2001
Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
2001 Aug
Radiation sensitization of mammalian cells by metal chelators.
2001 Feb
Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
2001 Feb 1
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
2001 Jul
The controversial role of deferiprone in the treatment of thalassemia.
2001 May
Chelation therapy in beta-thalassemia: an optimistic update.
2001 Oct
Antimalarial effect of iron chelators.
2002
Long term deferiprone chelation therapy.
2002
Effects of deferiprone on immune status and cytokine pattern in thalassaemia major.
2002
A postmodern moral tale: the ethics of research relationships.
2002 Apr
Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells.
2002 Apr
An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use.
2002 Apr 23
Anti-leukemia activity of 7-hydroxy-2-substituted-methyl-5H-oxazolo[3,2-a]pyrimidin-5-one derivatives.
2002 Dec
The deferiprone controversy: time to move on.
2002 Feb 19
Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone.
2002 Jan 15
Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
2002 Jul 15
Different complexation properties of some hydroxy keto heterocycles toward beryllium(II) in aqueous solutions: experimental and theoretical studies.
2002 Jul 29
Independent inquiry.
2002 Jul 9
I beg to differ.
2002 Jul 9
Orally active iron chelators.
2002 Jun
The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice.
2002 Mar 10
News article on report about drug researcher was biased.
2002 Mar 9
Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.
2002 Mar-Apr
Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
2003
Iron chelation in chemotherapy.
2003
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
2003
Iron chelating agents for treating malaria.
2003
[Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].
2003
Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
2003 Apr
Do we need more iron-chelating drugs?
2003 Aug 9
The Olivieri case.
2003 Feb 27
The Olivieri case.
2003 Feb 27
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
2003 Jan 11
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
2003 Jan 11
Pulmonary dysfunction in transfusion-dependent patients with thalassemia major.
2003 Jul 15
Iron-dependent activation of NF-kappaB in Kupffer cells: a priming mechanism for alcoholic liver disease.
2003 Jun
Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload.
2003 Jun
Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors.
2003 Jun 2
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
2003 May
Glutathione depletion increases nitric oxide-induced oxidative stress in primary rat hepatocyte cultures: involvement of low-molecular-weight iron.
2003 May 15
Pharmacotherapy of iron overload in thalassaemic patients.
2003 Oct
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
2003 Sep 1
Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs.
2004
Superoxide, H2O2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase.
2004 Mar
Patents

Sample Use Guides

25 mg/kg to 33 mg/kg body weight, orally, three times per day, for a total daily dose of 75 mg/kg to 99 mg/kg body weight.
Route of Administration: Oral
Proliferating CD4+ T cells from control and RRMS subjects, cultured with or without IL-2, decreased in response to 75 μM deferiprone, although the extent of decreased proliferation of CD4+ T cells from RRMS subjects was less than for control subjects. Proliferating CD8+ T cells from control subjects, cultured with or without IL-2, also decreased in response to 75 μM deferiprone, and this decrease was seen in proliferating CD8+ T cells from RRMS cultured with IL-2.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:47:54 GMT 2023
Edited
by admin
on Fri Dec 15 15:47:54 GMT 2023
Record UNII
2BTY8KH53L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEFERIPRONE
DASH   EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
4(1H)-PYRIDINONE, 3-HYDROXY-1,2-DIMETHYL-
Systematic Name English
DEFERIPRONE [EP MONOGRAPH]
Common Name English
NSC-758880
Code English
L-1
Code English
3-Hydroxy-1,2-dimethylpyridin-4(1H)-one
Systematic Name English
APO-66
Code English
DEFERIPRONE [MART.]
Common Name English
Deferiprone [WHO-DD]
Common Name English
L1
Code English
DEFERIPRONE [ORANGE BOOK]
Common Name English
3-HYDROXY-1,2-DIMETHYL-4(1H)-PYRIDONE
Systematic Name English
deferiprone [INN]
Common Name English
DEFERIPRONE [EMA EPAR]
Common Name English
CP-20
Code English
DN-180-01-AF
Code English
DEFERIPRONE [VANDF]
Common Name English
DN-18001AF
Code English
CP20
Code English
DEFERIPRONE [USAN]
Common Name English
APO-066
Code English
DEFERIPRONE [MI]
Common Name English
DEFERIPRON
Common Name English
PL1
Code English
PL-1
Code English
Classification Tree Code System Code
EU-Orphan Drug EU/3/10/832
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
NCI_THESAURUS C62357
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
FDA ORPHAN DRUG 340011
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
FDA ORPHAN DRUG 581217
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
FDA ORPHAN DRUG 264308
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
EMA ASSESSMENT REPORTS FERRIPOX (AUTHORIZED: BETA-THALASSEMIA)
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
LIVERTOX NBK548086
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
FDA ORPHAN DRUG 150701
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
NDF-RT N0000175522
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
WHO-ATC V03AC02
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
WHO-VATC QV03AC02
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
Code System Code Type Description
WIKIPEDIA
DEFERIPRONE
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
CAS
30652-11-0
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
ChEMBL
CHEMBL70927
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
CHEBI
68554
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
SMS_ID
100000085431
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
INN
6958
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
MESH
C044919
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
DRUG BANK
DB08826
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
RXCUI
11645
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m4132
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY Merck Index
IUPHAR
7456
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
DAILYMED
2BTY8KH53L
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
DRUG CENTRAL
4188
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
USAN
WW-29
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID6040666
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
EVMPD
SUB06941MIG
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
FDA UNII
2BTY8KH53L
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
NSC
758880
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
LACTMED
Deferiprone
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
NCI_THESAURUS
C73030
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
HSDB
8335
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
PUBCHEM
2972
Created by admin on Fri Dec 15 15:47:54 GMT 2023 , Edited by admin on Fri Dec 15 15:47:54 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MINOR
TARGET->LIGAND
METABOLIC ENZYME -> SUBSTRATE
MINOR
EXCRETED UNCHANGED
URINE
BINDER->LIGAND
BINDING
EXCRETED UNCHANGED
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC SINGLE DOSE IN THE FED STATE

Tmax PHARMACOKINETIC SINGLE DOSE IN FASTED HEALTHY SUBJECTS

Biological Half-life PHARMACOKINETIC